China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced an additional cooperation agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN), focusing on the development of a companion diagnostic (CDx). This collaboration builds upon a global strategic master collaboration agreement that was first signed at the end of 2021.
AmoyDxHRD Complete Panel as Companion Diagnostic for Lynparza
According to the latest agreement, AmoyDx’s self-developed product, the AmoyDxHRD Complete Panel, will serve as the companion diagnostic for Lynparza (Olaparib), a PARP inhibitor that is jointly developed and commercialized by AstraZeneca and MSD. Once approved, the AmoyDxHRD Complete Panel will play a crucial role in identifying patients who are most likely to benefit from treatment with Olaparib.
Lynparza’s Indications and HRD-Positive Cancer Treatment
Olaparib is approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab. The treatment is specifically for patients whose cancer is associated with a homologous recombination deficiency (HRD)-positive status. The use of the AmoyDxHRD Complete Panel as a companion diagnostic will enhance the precision of patient selection for this targeted therapy.-Fineline Info & Tech
